Outcomes in refractory diffuse large B-cell lymphoma
Oct 19 2017 · Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma. Although 5-year survival rates in the first-line setting range from 60 to 70 up to 50 of patients become refractory to or relapse after treatment. Published analyses of large-scale outcome data from patients with refractory DLBCL are limited.
Get Price
REFERENCESUpToDate
Diffuse large B cell lymphoma (DLBCL) is the most common histologic subtype of non-Hodgkin lymphoma (NHL). For patients who are refractory to initial treatment or relapse after an initial response only a small percentage will experience prolonged disease-free survival with salvage chemoimmunotherapy alone 1 .
Get Price
Risk Factors for Early Relapse of DLBCL After CAR-T
Nov 24 2020 · Vercellino L Di Blasi R Kanoun S et al. Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma
Get Price
POLA BR for Relapsed or Refractory DLBCLFull Text View
Sep 01 2020 · Brief Summary This is a phase II multicenter open-label study of polatuzumab vedotin administered by IV infusion in combination with standard doses of bendamustine (B) and rituximab (R) in transplant-eligible patients with relapsed or refractory DLBCL. A total of 22 patients will be enrolled over a period of 2 years through the University of
Get PricePOLA BR for Relapsed or Refractory DLBCLFull Text View
Sep 01 2020 · Brief Summary This is a phase II multicenter open-label study of polatuzumab vedotin administered by IV infusion in combination with standard doses of bendamustine (B) and rituximab (R) in transplant-eligible patients with relapsed or refractory DLBCL
Get Price
MT-3724 for Relapsed or Refractory DLBCL Molecular
Subjects must have relapsed or refractory diffuse large B-cell lymphoma (DLBCL) according to the Revised European American Lymphoma/World Health Organization (REAL/WHO) classification. Subjects must have received at least 2 standard of care regimens for NHL treatment. Subjects must have at least one tumor lesion at screening
Get PriceRelapsed/Refractory DLBCL Undergoes Rapid Evolution With
High-dose chemotherapy and transplant remains the second-line standard of care for the majority of patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) however CAR T-cell
Get Price
Relapsed/refractory diffuse large B-cell lymphoma
The clinical approach to relapsed/refractory DLBCL should include high-dose therapy and autologous stem cell transplantation (HD-ASCT) with curative intent in patients without comorbidities. Results from the recently reported CORAL study suggest that patients refractory to rituximab-containing regimens have inferior outcomes with HD-ASCT.
Get Price
CD19/CD22 Dual‐Targeted CAR‐T Therapy Active in Relapsed
Jun 26 2020 · The Alexander trial enrolled 23 patients with relapsed refractory or transformed DLBCL who experienced relapse after ≥2 prior lines of therapy or autologous stem cell transplant (ASCT). The median patient age was 57 years (range 28–83 years). The median number of prior therapies was 3 (range 2–10) and 4 patients had a prior ASCT.
Get PriceFDA approves first chemoimmunotherapy regimen for patients
Efficacy was evaluated in a study of 80 patients with relapsed or refractory DLBCL who were randomized to receive Polivy with BR or BR alone. Efficacy was based on complete response rate and
Get Price
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse
Dec 01 2018 · Abstract Background Patients with diffuse large B-cell lymphoma that is refractory to primary and second-line therapies or that has relapsed after stem-cell
Get Price
New drugs for the management of relapsed or refractory
May 04 2019 · Relapsed and refractory DLBCL standard approaches Other Section The majority of relapses occur within 2 to 3 years from completion of initial treatment although a low incidence of late
Get Price
Polatuzumab Vedotin in Relapsed or Refractory Diffuse
Patients with transplantation-ineligible relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) fare poorly with limited treatment options. The antibody-drug conjugate polatuzumab vedotin targets CD79b a B-cell receptor component.
Get Price
XPOVIO® (selinexor) Relapsed or Refractory DLBCL
XPOVIO is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified including DLBCL arising from follicular lymphoma after at least 2 lines of systemic therapy. These indications are
Get Price
New drugs for the management of relapsed or refractory
May 04 2019 · Relapsed and refractory DLBCL standard approaches Other Section The majority of relapses occur within 2 to 3 years from completion of initial treatment although a low incidence of late relapse exists (7). Patients with R-CHOP-refractory disease (1 2 8) have a particularly poor prognosis with a median OS of less than a year (913).
Get Price
Diffuse Large B-Cell Lymphoma Relapsed/Refractory
High-dose chemotherapy followed by stem cell transplantation can be used to treat patients with DLBCL whose disease is refractory or relapsed following initial chemotherapy.
Get Price
Understanding Diffuse Large B-Cell Lymphoma
with both newly diagnosed and relapsed/refractory DLBCL. Promising therapies in clinical trials being investigated eith er alone or in combination include MOR208 with lenalidomide (Revlimid) histone deacetylase (HDAC) inhibitors with and without B-cell lymphoma 2 (BCL2) inhibitors and Bruton tyrosine kinase (BTK) inhibitors such as ibrutinib.
Get Price
Tafasitamab plus lenalidomide in relapsed or refractory
Patients with relapsed or refractory diffuse large B-cell lymphoma who are ineligible for autologous stem-cell transplantation have poor outcomes and few treatment options.
Get Price
Therapeutic Options for Relapsed/Refractory Diffuse Large
Sep 10 2020 · One of the major breakthroughs in treatment for relapsed/refractory DLBCL has been the development of chimeric antigen receptor (CAR) T-cell therapy. Two products axicabtagene ciloleucel and tisagenlecleucel have been approved for this indication and both have demonstrated high rates of durable responses.
Get Price
Tafasitamab plus lenalidomide in relapsed or refractory
Patients with relapsed or refractory diffuse large B-cell lymphoma who are ineligible for autologous stem-cell transplantation have poor outcomes and few treatment options.
Get Price
Polatuzumab Vedotin in Relapsed or Refractory Diffuse
Patients with transplantation-ineligible relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) fare poorly with limited treatment options. The antibody-drug conjugate polatuzumab vedotin targets CD79b a B-cell receptor component.
Get PriceXPOVIO® (selinexor) Relapsed or Refractory DLBCL
to treat adults with certain types of diffuse large B-cell lymphoma (DLBCL) that has come back (relapsed) or that did not respond to previous treatment (refractory) and who have received at least 2 prior
Get Price
XPOVIO® (selinexor) Relapsed or Refractory Multiple Myeloma
XPOVIO is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified including DLBCL arising from follicular lymphoma after at least 2 lines of systemic therapy. These indications are
Get Price
FDA approves selinexor for relapsed/refractory diffuse
On June 22 2020 the Food and Drug Administration granted accelerated approval to selinexor (XPOVIO Karyopharm Therapeutics) for adult patients with relapsed or refractory diffuse large B-cell
Get Price
Tafasitamab plus lenalidomide in relapsed or refractory
Patients with relapsed or refractory diffuse large B-cell lymphoma who are ineligible for autologous stem-cell transplantation have poor outcomes and few treatment options.
Get Price
Management of relapsed/refractory DLBCLScienceDirect
Sep 01 2018 · Several salvage therapy regimens have been explored prior to ASCT. The main results of prospective studies in patients with relapsed/refractory DLBCL and eligible for transplantation are presented in Table 1. In the randomized phase III CORAL trial including 396 DLBCL patients in first relapse R-DHAP (dexamethasone cytarabine and cisplatine) and R-ICE (ifosfamide carboplatine
Get Price
Incidence of relapsed/refractory diffuse large B-cell
Jan 07 2021 · We performed a national population-based study of all patients diagnosed with diffuse large B-cell lymphoma (DLBCL) in Sweden in 2007–2014 to assess treatment intent and risk of relapsed/refractory
Get Price
Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Dec 10 2011 · The clinical approach to relapsed/refractory DLBCL should include high-dose therapy and autologous stem cell transplantation (HD-ASCT) with curative intent in patients without comorbidities. Results from the recently reported CORAL study suggest that patients refractory to rituximab-containing regimens have inferior outcomes with HD-ASCT.
Get Price
Efficacy of Axicabtagene Ciloleucel Compared to Standard
Jan 05 2018 · Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Biological Axicabtagene Ciloleucel Drug Platinum-containing salvage chemotherapy (eg R-ICE) followed by high dose therapy (eg BEAM) and autologous stem cell transplant in responders. Drug Cyclophosphamide Drug Fludarabine Phase 3
Get Price
